Related Experiment Video
Updated: Jun 30, 2025
Establishment and Genetic Manipulation of Murine Hepatocyte Organoids
Published on: February 12, 2022
Molecular Insights of Cholestasis in MDR2 Knockout Murine Liver Organoids
Irene Blázquez-García1, Laura Guerrero1, Cristina Cacho-Navas2
1Functional Proteomics Laboratory, Centro Nacional de Biotecnología (CSIC), Madrid 28049, Spain.
Abstract:
MDR3 (multidrug resistance 3) deficiency in humans (MDR2 in mice) causes progressive familial intrahepatic cholestasis type 3 (PFIC3). PFIC3 is a lethal disease characterized by an early onset of intrahepatic cholestasis progressing to liver cirrhosis, a preneoplastic condition, putting individuals at risk of hepatocellular carcinoma (HCC). Hepatocyte-like organoids from MDR2-deficient mice (MDR2KO) were used in this work to study the molecular alterations caused by the deficiency of this transporter. Proteomic analysis by mass spectrometry allowed characterization of 279 proteins that were differentially expressed in MDR2KO compared with wild-type organoids. Functional enrichment analysis indicated alterations in three main cellular functions: (1) interaction with the extracellular matrix, (2) remodeling intermediary metabolism, and (3) cell proliferation and differentiation. The affected cellular processes were validated by orthogonal molecular biology techniques. Our results point to molecular mechanisms associated with PFIC3 that may drive the progression to liver cirrhosis and HCC and suggest proteins and cellular processes that could be targeted for the development of early detection strategies for these severe liver diseases.
Insights
MDR3 deficiency causes progressive familial intrahepatic cholestasis type 3 (PFIC3), leading to liver cirrhosis and cancer. This study identified molecular changes in mouse organoids, revealing potential targets for early detection and treatment of PFIC3-related liver diseases.
Area of Science:
- Hepatology and Molecular Biology
- Genetics and Genomics
Background:
- Progressive familial intrahepatic cholestasis type 3 (PFIC3) is a severe, lethal liver disease caused by MDR3 deficiency.
- PFIC3 leads to intrahepatic cholestasis, liver cirrhosis, and increased risk of hepatocellular carcinoma (HCC).
Purpose of the Study:
- To investigate the molecular mechanisms underlying PFIC3 using a mouse model.
- To identify potential therapeutic targets for PFIC3 and its complications.
Main Methods:
- Utilized hepatocyte-like organoids derived from MDR2-deficient mice (MDR2KO).
- Performed proteomic analysis via mass spectrometry to identify differentially expressed proteins.
- Validated key findings using orthogonal molecular biology techniques.
Main Results:
- Characterized 279 differentially expressed proteins in MDR2KO organoids compared to wild-type.
- Identified significant alterations in extracellular matrix interaction, intermediary metabolism, and cell proliferation/differentiation.
- Confirmed molecular pathways implicated in PFIC3 progression.
Conclusions:
- Discovered molecular mechanisms driving PFIC3 progression towards liver cirrhosis and HCC.
- Identified potential protein and cellular targets for developing early detection strategies for PFIC3-related liver diseases.
